X
01May

CTS Implements HLA Class I and II Testing on the Gemini

0 Comments | | Return |

CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini on Monday, April 29th. As previously communicated, the Immucor assay and sample requirements are the same, and the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list are now available on our website.

 

 

 

 

Related

Reminder- ZIKV Testing Strategy Webinar Wednesday 8/15/18

Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...

Read More >

Reminder- The CTS Reentry form- CTS-00172 implements 7/2/18

Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...

Read More >

FDA Releases ZIKV Guidance and Grifols ZIKV Assay Licensed- 1st Update

This is the first update to the original CTS communication distributed on July 6th. As previously co...

Read More >

Reminder- Re-entry Webinar

Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...

Read More >

Reminder-CTS Testing Algorithm to be Revised on December 17, 2018

The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...

Read More >

Reminder- Health and Human Services (HHS) email notifications for WNV reactives

Reminder test email for the Health and Human Services (HHS) email notifications for WNV reactives wa...

Read More >

Subscribe here to receive CTS updates!

Name